Article

Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseases

2023-06-03

Abstract excerpt

<h4>Background</h4> RNA-based, antibody-based and gene editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular diseases (ASCVD) risk. We used Mendelian randomization (MR) to determine whether genetic variations influencing ANGPTL3 liver gene expression, blood levels an...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f4bf1212-6674-5b0c-b02f-04a60ba22630
DOI: 10.1101/2023.05.29.23290580

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseasesDOI 10.1101/2023.05.29.23290580Read

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic riskSemantic proximity Read

The Genetic Revolution in Cardiometabolic Disease: A Review of Novel RNA and Gene‐Editing Therapies Targeting APOC3, ANGPTL3, and Lp(a)Semantic proximity Read

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.Semantic proximity Read

Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysisSemantic proximity Read

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.Semantic proximity Read

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular DiseasesSemantic proximity Read

Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery diseaseSemantic proximity Read

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases preventionSemantic proximity Read

Impact of loss-of-function in angiopoietin-like 4 on the human phenomeSemantic proximity Read